LIG3 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 4.98120433789495E-11 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
7.15200000334093E-08 |
Normal-vs-Stage2 |
3.614300E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.844170E-02 |
Stage1-vs-Stage2 |
5.315800E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
4.384200E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
3.066400E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
2.47450004930982E-09 |
Normal-vs-AfricanAmerican |
7.418100E-02 |
Normal-vs-Asian |
1.508770E-01 |
Caucasian-vs-AfricanAmerican |
4.949600E-01 |
Caucasian-vs-Asian |
9.755000E-01 |
AfricanAmerican-vs-Asian |
5.777400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
6.1845999999921E-05 |
Normal-vs-Female |
3.5331999992394E-08 |
Male-vs-Female |
2.647000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
6.920100E-03 |
Normal-vs-Extreme_Weight |
1.20909999790086E-08 |
Normal-vs-Obese |
2.261800E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
7.271900E-02 |
Normal_Weight-vs-Obese |
2.248000E-02 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
1.284410E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.684230E-01 |
Normal-vs-Age(41-60Yrs) |
6.09209999999916E-05 |
Normal-vs-Age(61-80Yrs) |
1.89074999999983E-05 |
Normal-vs-Age(81-100Yrs) |
2.363800E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.779200E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.647600E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.941600E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.945400E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.036200E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.045600E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
5.352600E-01 |
Normal-vs-Grade 3 |
6.042400E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
1.563160E-01 |
Grade 2-vs-Grade 4 |
5.352600E-01 |
Grade 3-vs-Grade 4 |
6.042400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
8.58230042588559E-10 |
Normal-vs-N1 |
1.782190E-02 |
N0-vs-N1 |
1.419800E-01 |
|
|